Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin

Bibliographische Detailangaben
Veröffentlicht in:	Clinical immunology (Orlando, Fla.). - 1999. - 230(2021) vom: 05. Sept., Seite 108826
1. Verfasser:	Esmaeilzadeh, Hossein (VerfasserIn)
Weitere Verfasser:	Askarisarvestani, Aida, Hosseini, Nazanin, Samimi, Sahar, Shafiei, Alireza, Mahdaviani, Seyed Alireza, Eslami, Narges, Chavoshzadeh, Zahra, Fallahi, Mazdak, Khakbazanfard, Nasrin, Shabestari, Mahnaz Sadeghi, Aleyasin, Soheila, Nabavizadeh, Seyed Hesamedin, Cheraghi, Taher, Kalantari, Arash, Ahmadiafshar, Akefeh, Safari, Mojgan, Eslamian, Mohammad Hossein, Molatefi, Rasol, Shirkani, Afshin, Heidarzadeh Arani, Marzieh, Tavakol, Marzieh, Bemanian, Mohammad Hassan, Arshi, Saba, Nabavi, Mohammad, Shokri, Sima, Shahhosseini, Babak, Mortazavi, Negar, Nakhaei, Pooria, Nazari, Farzad, Fallahpour, Morteza, Ahanchian, Hamid, Moazzen, Nasrin, Khoshkhui, Maryam, Motlagh, Ahmad Vosughi, Aghamohammadi, Asghar, Abolhassani, Hassan, Yazdani, Reza, Rezaei, Nima
Format:	Online-Aufsatz
Sprache:	English
Veröffentlicht:	2021
Zugriff auf das übergeordnete Werk:	Clinical immunology (Orlando, Fla.)
Schlagworte:	Journal Article Multicenter Study Research Support, Non-U.S. Gov't Adverse reaction Inborn errors of immunity Intravenous immunoglobulins Iran Primary immunodeficiencies Immunoglobulins, Intravenous

Beschreibung
Zusammenfassung:	Copyright © 2021 Elsevier Inc. All rights reserved. BACKGROUND: Intravenous immunoglobulins (IVIg) are the major treatment in inborn errors of immunity (IEI) disorders; However, IVIg infusions show some adverse effects. We aimed to assess the adverse reactions of IVIg infusions METHODS: Data of IVIg infusions in IEI patients were collected from 2011 to 2021. Totally, 363 IEI patients received IVIg regularly in Iran entered the study. The adverse reactions are classified regarding their severity and chronicity RESULTS: 22,667 IVIg infusions were performed in the study. 157 patients (43.2%) and 1349 (5.9%) infusions were associated with at least one type of adverse reaction. The highest rates of adverse reactions were seen in severe combined immunodeficiency. Myalgia, chills, headache, fever, and hypotension were the most frequent adverse effects of IVIg CONCLUSION: The reactions affect almost half of the patients mainly in the first infusions which necessitate the close observation of IEI patients receiving IVIg
Beschreibung:	Date Completed 13.09.2021 Date Revised 13.09.2021 published: Print-Electronic Citation Status MEDLINE
ISSN:	1521-7035
DOI:	10.1016/j.clim.2021.108826